Xeris Biopharma, Inc.

154 articles with Xeris Biopharma, Inc.

• Xeris Pharmaceuticals Reports Fourth Quarter and Full-year 2020 Financial Results and Recent Highlights

  3/9/2021

  Gvoke® net sales of $20.2 million for full-year 2020 Continued Gvoke prescription growth – over 350% in 2020 Strong cash position of $133.8 million Conference call and webcast today at 8:30 a.m. ET

• Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on March 9, 2021

  3/2/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its fourth quarter and full-year 2020 financial results before the open of the U.S. financial markets on Tuesday, March 9, 2021.

• Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Feb 26, 2021

  2/26/2021

  Xeris Pharmaceuticals, Inc. announced that on February 24, 2021, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 5,000 shares, and restricted stock units for an aggregate of 9,500 shares, of its common stock to 3 new employee under Xeris’ Inducement Equity Plan.

• Xeris Pharmaceuticals to Webcast Upcoming Investor Conference Presentations

  2/18/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the following upcoming investor conferences:

• Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

  2/12/2021

  Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced that the European Commission has approved Ogluo™ injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

• Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 29, 2021

  1/29/2021

  Xeris Pharmaceuticals, Inc. announced that on January 27, 2021, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 16,000 shares of its common stock to 38 new employee under Xeris’ Inducement Equity Plan.

• Xeris Pharmaceuticals Announced Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  12/31/2020

  Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on December 30, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 38,250 shares, and restricted stock units for an aggregate of 35,100 s

• Xeris Pharmaceuticals Announces Distribution Agreement With Megapharm Ltd. to Commercialize Gvoke® in Israel and the Palestinian Authority

  12/22/2020

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has entered into an exclusive distribution agreement with Megapharm Ltd.

• Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo™, Its Ready-To-Use (RTU) Glucagon for Injection, for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

  12/11/2020

  Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced that yesterday the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive Opinion for Ogluo™.

• Xeris Pharmaceuticals Announces Grants Under NASDAQ Listing Rule 5635(c)(4)

  11/27/2020

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on November 25, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 18,000 shares, and restricted stock units for an aggregate of 70,200 s

• Xeris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights

  11/9/2020

  Gvoke® net sales grew 370% quarter over quarter to $9.4 million driven by launch of Gvoke HypoPen® Company to host a conference call and webcast today at 8:30 a.m. ET

• 

  FDA Awards Fast Track Designation to Multiple Non-COVID-19 Candidates

  11/4/2020

  While the world has largely been focused on the development of vaccines and therapeutics for COVID-19, the U.S. FDA has remained busy lining up potential approvals of medications for other diseases and illnesses.

• Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Oct 30, 2020

  10/30/2020

  Xeris Pharmaceuticals, Inc. announced that on October 28, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 36,250 share of its common stock to 15 new employee under Xeris’ Inducement Equity Plan.

• Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection

  10/20/2020

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it was granted Fast Track designation by the Food and Drug Administration (FDA) for the investigation of XP-0863 (diazepam non-aqueous injection) for the treatment of acute repetitive seizures.

• Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Oct 02, 2020

  10/2/2020

  Xeris Pharmaceuticals, Inc. announced that on September 30, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 250 share of its common stock to 1 new employee under Xeris’ Inducement Equity Plan.

• Xeris Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

  9/8/2020

  Xeris Pharmaceuticals to Present at the H.C. Wainwright 22 nd Annual Global Investment Conference

• Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Aug 28, 2020

  8/28/2020

  Xeris Pharmaceuticals, Inc. announced that on August 26, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 500 share of its common stock to 1 new employee under Xeris’ Inducement Equity Plan.

• Xeris Pharmaceuticals Appoints John Shannon President and Chief Operating Officer

  8/20/2020

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today announced that its Board of Directors has promoted John P. Shannon to the position of President and Chief Operating Officer, effective immediately. In his new role, Mr. Shannon will be responsible for

• Xeris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Highlights

  8/10/2020

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today announced financial results for the second quarter and six months ended June 30, 2020, as well as pipeline and corporate highlights.

• Xeris Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020

  8/3/2020

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its second quarter 2020 financial results before the open of the U.S. financial markets on Monday, August 10, 2020.